Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
The Lancet Oncology,  Clinical Article

Zhang L et al. – Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy.

Methods

  • Patients were aged 18 years or older, were of east Asian ethnic origin, had a life expectancy of more than 12 weeks, histologically or cytologically confirmed stage IIIb or IV NSCLC, a WHO performance status of 0—2, and had completed four cycles of first-line platinum-based doublet chemotherapy without disease progression or unacceptable toxic effects.
  • Between Sept 28, 2008 and Aug 11, 2009, 296 patients were randomly assigned 1:1 to receive either gefitinib (250 mg per day orally) or placebo (orally) within 3—6 weeks after chemotherapy until progression or unacceptable toxic effects.
  • Randomisation was done via an interactive web response system with computer-generated randomisation codes.
  • Our primary endpoint was progression-free survival assessed in the intention-to-treat population.

Results
  • Progression-free survival was significantly longer with gefitinib (n=148) than with placebo (148) (median progression-free survival 4·8 months [95% CI 3·2—8·5] vs 2·6 months [1·6—2·8]; hazard ratio [HR] 0·42, 95% CI 0·33—0·55; p<0·0001).
  • Adverse events occurred more frequently with gefitinib than with placebo; the most common adverse events of any grade were rash (73 [50%] of 147 in the gefitinib group vs 14 [9%] of 148 in the placebo group), diarrhoea (37 [25%] vs 13 [9%]), and alanine aminotransferase increase (31 [21%] vs 12 [8%]).
  • The most commonly reported grade 3 or 4 adverse event was alanine aminotransferase increase (3 [2%] of 147 in the gefitinib group, none of 148 in the placebo group).
  • Ten of 147 (7%) patients given gefitinib and five of 148 (3%) patients given placebo had serious adverse events.
  • Three deaths were thought to be related to treatment with gefitinib: one from interstitial lung disease; one from lung infection; and one from pneumonia.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 One injection stops diabetes in its tracks Salk Institute News, July 18, 2014

2 FDA approves Afrezza to treat diabetes Full Text FDA Press Announcements, June 30, 2014    Free full text

3 Antibiotic developed 50 years ago may be the key to fighting 'superbugs' University at Buffalo Health and Medicine News, June 19, 2014

4 Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder Annals of Pharmacotherapy, July 25, 2014    Review Article    Clinical Article

5 New research indicates statin drugs must be taken properly Michigan State University Health News, July 22, 2014

6 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

7 European Commission approves Bristol-Myers Squibb’s Daklinza (daclatasvir) across multiple genotypes for the treatment of chronic hepatitis C infection Full Text Bristol Myers-Squibb, August 28, 2014    Free full text

8 “Worm pill” could ease autoimmune disease symptoms Monash University News, August 11, 2014

9 Honey as an effective antimicrobial treatment for chronic wounds Full Text Chronic Wound Care Management and Research, August 21, 2014    Free full text    Review Article

10 FDA approves new type of sleep drug, Belsomra Full Text FDA Press Announcements, August 14, 2014    Free full text

11 Is the standard dose of amoxicillin-clavulanic acid sufficient? Full Text BMC Pharmacology & Toxicology, August 8, 2014    Free full text    Clinical Article

12 Acetaminophen plus ibuprofen versus opioids for treatment of post-tonsillectomy pain in children International Journal of Pediatric Otorhinolaryngology , August 18, 2014    Clinical Article

13 Update on recommendations for use of herpes zoster vaccine Full Text Morbidity and Mortality Weekly Report, August 22, 2014    Free full text

14 Comparison of new-onset gout in adults prescribed chlorthalidone vs hydrochlorothiazide for hypertension The Journal of Clinical Hypertension, September 26, 2014    Clinical Article

15 FDA approves Jardiance to treat type 2 diabetes Full Text FDA Press Announcements, August 4, 2014    Free full text

16 Intracranial hemorrhage risk with the new oral anticoagulants: A systematic review and meta-analysis Journal of Neurology, September 2, 2014    Evidence Based Medicine    Review Article

17 Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis Heart Failure Reviews, July 28, 2014    Evidence Based Medicine    Review Article    Clinical Article

18 FDA approves Striverdi Respimat to treat chronic obstructive pulmonary disease Full Text FDA Press Announcements, August 1, 2014    Free full text

19 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT Journal of the American Society of Hypertension, September 15, 2014    Clinical Article

20 Digoxin tied to increased risk of death in patients with atrial fibrillation Stanford School of Medicine News, August 12, 2014

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close